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Background: As stereotactic body radiotherapy (SBRT) is a highly dose-dense radiotherapy, adverse events of
neighboring normal tissues are a major concern. This study thus aimed to clarify the frequency and degree of
clinical symptoms in patients with rib fractures after SBRT for primary lung cancer and to reveal risk factors for rib
fracture. Appropriate α/β ratios for discriminating between fracture and non-fracture groups were also investigated.
Methods: Between November 2001 and April 2009, 177 patients who had undergone SBRT were evaluated for clinical
symptoms and underwent follow-up thin-section computed tomography (CT). The time of rib fracture appearance was
also assessed. Cox proportional hazard modeling was performed to identify risk factors for rib fracture, using
independent variables of age, sex, maximum tumor diameter, radiotherapeutic method and tumor-chest wall distance.
Dosimetric details were analyzed for 26 patients with and 22 randomly-sampled patients without rib fracture.
Biologically effective dose (BED) was calculated with a range of α/β ratios (1–10 Gy). Receiver operating characteristics
analysis was used to define the most appropriate α/β ratio.
Results: Rib fracture was found on follow-up thin-section CT in 41 patients. The frequency of chest wall pain in patients
with rib fracture was 34.1% (14/41), and was classified as Grade 1 or 2. Significant risk factors for rib fracture were
smaller tumor-chest wall distance and female sex. Area under the curve was maximal for BED at an α/β ratio of 8 Gy.
Conclusions: Rib fracture is frequently seen on CT after SBRT for lung cancer. Small tumor-chest wall distance and
female sex are risk factors for rib fracture. However, clinical symptoms are infrequent and generally mild. When using
BED analysis, an α/β ratio of 8 Gy appears most effective for discriminating between fracture and non-fracture patients.
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Stereotactic body radiotherapy (SBRT) has emerged as a
new treatment for stage I lung cancer. Various articles
have reported promising treatment effects [1-6]. SBRT
has now come to be applied not only to medically in-
operable patients, but also to operable patients. In the* Correspondence: nambu-a@gray.plala.or.jp
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reproduction in any medium, provided the ornear future, SBRT may become feasible as an alternative
to surgery for stage I non-small lung carcinoma.
Posttreatment sequelae represent an important aspect
of treatment that should always be taken into account
when choosing treatment options. As SBRT is an ex-
tremely dose-dense therapy, very high doses are received
by normal structures adjacent to the irradiated tumor.
Various unpredictable adverse events may thus arise
after SBRT. Several studies have reported complications
related to SBRT for lung cancer, including radiation
pneumonitis [7] and chest wall injuries such as rib frac-
ture [8-10]. The reported frequencies of rib fracture after
SBRT are generally higher than those associated withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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irradiation in breast-conserving therapy. However, the
reported frequencies differ widely among investigators.
We speculated that such discrepancies might be largely
attributable to differences in the methods used to obtain
the frequencies, with authors calculating frequencies
based on symptomatic patients tending to report lower
frequencies than using follow-up computed tomography
(CT). That is, a substantial number of patients with rib
fracture appear asymptomatic. If an adverse event often
proves asymptomatic, clinicians should not overemphasize
the risks.
The present study therefore aimed to clarify the fre-
quency and degree of clinical symptoms in patients with
rib fracture and related chest wall injuries found on
follow-up CT after SBRT. In addition, we tried to identify
the threshold biologically effective dose (BED) for rib frac-
ture after SRT and risk factors for rib fracture.
Methods
All study protocols including chart review were approved
by the institutional review board, and written informed
consent was obtained from each patient for both SBRT
and participation in this investigation of SBRT-related rib
fracture. Clinical symptoms and imaging findings were
investigated prospectively, while dosimetric details were
reviewed retrospectively.
Patients
Between November 2001 and April 2009, a total of 210
patients with primary non-small cell lung carcinoma
underwent SBRT as the first treatment with a curative
intent in our institution. Of these, 177 patients agreed to
participate in this study. The remaining 33 patients did
not participate because they were unable to visit our
hospital as required in the schedule defined in the study
protocol.Table 1 Characteristics of the 177 primary lung cancer patien
Mean age (range)
Gender (male: female)
Pathology of the tumor (Ad: SCLC: SCC:spindle cell carcinoma*: unspecified**
Tumor diameter (average ± standard deviation)
Tumor-chest wall distance (median)
**Range of follow-up period (median)
Method of radiotherapy (48 Gy/4fr:60Gr/10fr:70Gr/10fr)
BED10 of the isocenter (median)
Abbreviations: Ad = adenocarcinoma, SCLC = small cell lung cancer, SCC = squamous
*Suspicious of pleomorphic carcinoma, but a definitive diagnosis was not made bec
**“unspecified” indicates pathologically definitive non-small cell lung carcinoma, bu
***“unknown” indicates clinically highly suspicious for lung cancer but no pathologRadiotherapeutic methods
SBRT was performed using noncoplanar dynamic arcs or
multiple static ports. A total dose of 48–70 Gy at the iso-
center was administered in 4–10 fractions at the minimum
dose point in the planning target volume (PTV) using a
6-MV X-ray, comprising three different methods: 48 Gy/4
fractions; 60 Gy/10 fractions; and 70 Gy/10 fractions
(Table 1). The border of the PTV was almost on the 80–
85% isodose line of the global maximum dose in the PTV.
After adjusting the isocenter of the PTV to the
planned position with a unit comprising a CT scanner
and linear accelerator, irradiation was performed under
patient-controlled breath-holding and gated radiation
beam switching.
Follow-up of patients
Every patient was basically asked to visit our clinic at 3
and 6 months after the completion of radiotherapy, and
every 6 months thereafter. At every visit, a thorough
examination was performed, consisting of inquiry focusing
on pain at the chest wall near the irradiated tumor and re-
spiratory symptoms, physical examination by an attending
radiation oncologist, blood testing, and CT. Clinical symp-
toms considered related to chest wall injury after SBRT
were graded according to the criteria for pain in Common
Terminology Criteria for Adverse Events, version. 3. Chest
radiologists interpreted the results of CT just after the
examinations. If the patient complained of pain, analgesics
were prescribed as appropriate.
CT examination
Preradiotherapeutic and follow-up CT were performed
using a 16 multidetector row scanner (Aquilion 16;
Toshiba Medical Systems, Otawara, Japan). The para-
meters for CT were as follows: peak voltage, 120 kVp; tube
rotation time, 0.5 second; slice collimation,1.0 mm (identi-
cal to reconstruction slice thickness and slice interval);ts and the tumors
Lung cancer patients (n = 177)
77.3 ± 7.0 (55–92)
132:45
:unknown***) 89:7:47:1:9:24





cell carcinoma, BED = biologically effective dose.
ause of needle biopsy.
t unspecified for the subtype.
y obtained.
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an automatic exposure control in the CT machine and the
tube current showing actual range of 110–400 mA.
Contrast-enhanced CT was performed in 116 patients
(67.1%) after unenhanced CT.
Data were reconstructed into 5-mm sections. Thin-
section CT (slice thickness, 1 mm) was also produced for
the regions that included the tumor or radiation-induced
opacities targeting the affected lung.
Preradiotherapeutic CT was performed within 1 month
before SRT, while follow-up CT was performed at 3 and
6 months and every 6 months thereafter.
Methods of CT evaluation
Serial follow-up CT was evaluated regarding the presence
or absence of rib fractures and chest wall edema near the
irradiated tumor in addition to routine radiological assess-
ment by either of two board-certified chest radiologists at
our clinic. Rib fracture was defined as a disruption of cor-
tical continuity with malalignment. Distance between the
tumor and chest wall (tumor-chest wall distance) was also
measured on preradiotherapeutic CT. The time at which
each finding first appeared after the completion of SBRT
was reviewed later. Presence or absence of pulmonary em-
physema and maximum transverse diameter of the tumor
were also assessed on pre-radiotherapeutic CT.
Evaluation of dosimetry
Among the 177 patients, dosimetric details were avail-
able for review in 26 patients with rib fracture and 22
patients without rib fracture (Figure 1A). Patients with-
out fracture were randomly sampled among those with
no evidence of fracture on CT for >30 months. We set
this period as a cut-off point as most rib fractures after
SRT in this series had occurred within 30 months afterA
Figure 1 An 86-year-old woman with adenocarcinoma after SRT. A) D
prescribed dose to the chest wall as 63 Gy, with a BED3 of 233.2 Gy. The si
B) Rib fracture was noted at 24 months after completion of SRT. Amorphocompletion of SBRT. We were unable to obtain dosimet-
ric data for the remaining patients because of break-
down of the data during the review of dosimetry. At the
point that had received the maximum dose in the chest
wall consisting of parietal pleura, ribs and intercostal
muscles, BED was calculated in each case using a range
of α/β ratios (1–10 Gy), to clarify which α/β ratio was
most effective for evaluating the risk of rib fracture.
Data analysis
First, we calculated the incidence of rib fracture after
SBRT on follow-up CT in the given follow-up periods of
the patients. Incidence of rib fracture was also assessed in
relation to tumor-chest wall distance, and the time of rib
fracture appearance was evaluated. Incidence of rib frac-
ture was also estimated by using a Kaplan-Meier method.
Second, we calculated the frequency of clinical symp-
toms in patients with and without rib fractures.
Third, Cox proportional hazard model was used to iden-
tify risk factors associated with rib fracture after SBRT.
The independent variables tested comprised age, sex,
maximum tumor diameter, radiotherapeutic method, and
tumor-chest wall distance, for which the proportionalities
of hazards had been confirmed using a Kaplan-Meier
method. As there were three radiotherapeutic methods,
we used two dummy variables to represent them.
Fourth, receiver operating characteristic (ROC) ana-
lysis was undertaken for maximum BED of the chest
wall at each α/β ratio. For BED at the α/β ratio that pro-
vided the largest area under the curve, we calculated the
cut-off dose that most effectively differentiated between
fracture and non-fracture patients. This was regarded as
the dose at the point closest in rectilinear distance on
the ROC curve to point 1.0 on the vertical axis, where
both sensitivity and specificity become 1.0.B
osimetry overlaying CT with a bone window shows the maximum
te of rib fracture later is indicated by a black elliptical cercle.
us osteosclerosis is also seen (arrow).




group (n = 41)
Frequency in non-fracture
group (n = 136)
Rib fractures 4–58 41 (100)* 0 (0)
Chest wall edema 2–57 35 (85.4) 10 (7.4)
*The numbers in the parentheses in the frequencies of findings are percentages.
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of rib fracture appearance and BED at the α/β ratio
defined above in the 26 patients with rib fracture using
Pearson’s correlation coefficient.
Values of p <0.05 were considered significant in all
analyses. All statistical analyses were performed using
IBM SPSS Statistics version 18 software (IBM, New
York, USA).Results
Patient demographics
Patient demographics and tumor characteristics are
summarized in Table 1. Local control rates were 91% at
1 year and 83% at 3 years (detailed data not shown).
Incidence of rib fractures after SRT
Incidence of rib fracture was 23.2% (41/177) at a median
follow-up period of 33 months (range, 24–94 months)
(Figure 1). When the tumor-chest wall distance was ≤25
mm, the incidence was 27.8% (41/148). The frequency
of rib fracture rose to 31.3% for a distance of ≤16 mm
(41/131). No patients with a distance >16 mm deve-
loped a rib fracture. When the distance was 0, the fre-
quency of rib fracture was 36.7% (22/60). Kaplan-Meier
method estimated the incidence to be 27.4% at 24 months.
Time-to-event for rib fracture and chest wall edema
Durations to rib fracture and other related findings are
summarized in Table 2. Three patients showed rib frac-A
Figure 2 A 64-year-old man with adenocarcinoma after SRT. A) At 3 m
suspicious findings in the left chest wall, such as slight asymmetry and ind
contrast-enhanced CT shows definitive chest wall edema, evidenced by sw
No rib fracture was seen at this time.tures ≥30 months after completion of SBRT, at 37, 53 and
58 months.
Chest wall edema was seen in 45 of 177 patients (25.4%),
arising at a mean of 12 months (range, 2–57 months)
(Figure 2), and appearing as asymmetrical swelling of the
ipsilateral chest wall with low attenuation areas compared
to the contralateral side.
Symptoms of rib fracture
Clinical symptoms in patients with rib fracture and with-
out rib fracture are summarized in Table 3. No patients
complained of Grade 3 or more symptoms. Four patients
without rib fractures complained of Grade 1 chest wall
pain with all 4 cases showing radiological evidence of
chest wall edema. In the study population as a whole,
the frequency of chest wall pain was 21.5% (38/177).
Among patients with peripheral tumors that had a tumor-
chest wall distance ≤25 mm, the frequency of chest pain
was 25.7%.
Risk factors of rib fracture after SBRT
The results of Cox proportional hazard modeling are
summarized in Table 4. Tumor-chest wall distance and
sex were significant risk factors for rib fracture.
Area under the curve ranged from 0.781 to 0.865 and
was largest for an α/β ratio of 8 Gy (BED8). A BED8
value of 115.0 Gy was the most discriminative value be-
tween fracture and non-fracture patients, yielding 73%
sensitivity and 91% specificity. The lowest BED8 that
resulted in rib fracture was 91.1 Gy. BED8 did notB
onths after completion of SRT, contrast-enhanced CT shows
istinct intermuscular fat planes (arrows). B) At 15 months after SRT,
elling of the left chest wall with an area of low attenuation (arrows).
Table 3 Frequency and degree of chest wall pain
Degree of pain* Fracture group (n = 41) Non-fracture group (n = 136)
Grade 0 27 (65.9)** 132 (97)
Grade 1 7 (17.1) 4 (3)
Grade 2 7 (17.1) 0 (0)
Grade 3 and 4 0 (0) 0 (0)
*The degree of chest wall pain was evaluated according to Common Terminology Criteria for Adverse Events, Ver. 3.
**The numbers in the parentheses are percentages.
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pearance (r = −0.362, p = 0.070).
Discussion
The frequency of rib fracture was 23.2% in our series. In
Kaplan-Meier method, it was estimated to be 27.4% at
24 months after the SBRT. Reported frequencies of rib
fracture after SBRT differ markedly among investigations,
ranging from 3% to 21.2% [8-10]. Our result is closest to
that described by Petterson et al., who reported the high-
est frequency of 21.2% by examining the results of follow-
up CT [9]. We speculate that these discrepancies between
studies are mainly attributable to differences in the me-
thods of estimating frequency. Both Petterson, et al. and
the present study obtained the frequency using follow-up
CT, whereas other investigations have determined fre-
quencies by confirming the presence of rib fracture on
chest radiographs in patients complaining of chest pain.
That is, asymptomatic patients with rib fracture may
largely account for these discrepancies. In fact, only 34.1%
of patients with rib fractures displayed clinical symptoms
in our series. Differences in follow-up period, method of
SRT and proportion of tumors close to chest wall may
have also contributed to the discrepancies.
The frequency of chest wall pain was 21.5% (38/177) in
our series. When confined to patients with a tumor-chest
wall distance ≤25 mm, the frequency was 25.7%. Dunlap
et al. observed that 17 of 60 patients (28%) with a periph-
eral tumor <2.5 cm from the chest wall had Grade 3 pain
and another 3 patients (5%) had Grade 1 or 2 pain in the
median follow-up period of 11.1 months. Frequency of
chest wall pain in total was 33% in that series, higher thanTable 4 Results of Cox proportional hazard model analysis
Independent valuable P value
Tumor-chest wall distance (mm) <0.0001
Age 0.713
Gender* 0.002
Maximum diameter of the tumor 0.754
Radiotherapeutic method 48 Gy or not 0.829
Radiotherapeutic method 60 Gy or not 0.087
*The hazard ratio for gender is represented as the hazard of women divided by thathe present study (25.7%) despite the fact that the median
follow-up period in that study was much shorter than that
in the present study. Furthermore, Grade 3 pain was
present in a higher proportion of the subjects in their
study, compared to our investigation. We speculate that
this difference is mainly due to differences in radiotherapy.
BEDs at the isocenter seem much higher with the method
applied by Dunlap et al.
Rib fracture is considered a common adverse event on
CT after SBRT for lung cancer. However, the frequency
of chest wall pain in patients with rib fracture was only
34.2%. Furthermore, pain was generally mild and usually
controllable using non-opioid analgesics in our series.
Reducing a prescribed dose to avoid rib fracture to such
a degree the tumor may be unsatisfactorily irradiated is
not justified, but using more fractions with reduced dose
might help to avoid adverse events. Also, it should also
be noted that the frequency and degree of chest wall
pain are greatly dependent on the total dose or fractions.
Our BED10 at the isocenter ranged from 96 to 119 Gy,
which may be one of the safe ranges in terms of avoiding
adverse events.
Little is known about the mechanisms by which pain is
induced in chest wall injury. As most symptomatic patients
had rib fracture in our series, fracture pain would be a
plausible contributing factor. An animal study suggested
that activation of nociceptors by mechanical stimulation or
an influx of hematological and inflammatory cells into the
fracture site is responsible for the pain related to fracture
[11]. In contrast to rib fractures caused by trauma, those
after SBRT are considered to involve a relatively chro-
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irritated, particularly in non-weight-bearing bones like ribs.
In addition, radiation-induced microcapillary injury may
hamper recruitment of inflammatory cells at the site of
fracture in the chronic stage, which in turn may also result
in less pain.
Four patients without rib fracture complained of Grade
1 pain. These patients showed evidence of chest wall
edema on follow-up CT. Chest wall inflammation or con-
traction of the tissue due to fibrosis, which could irritate
nerves, could be another factor contributing to chest wall
pain.
Cox proportional hazard analysis showed that smaller
tumor-chest wall distance and female sex were inde-
pendent risk factors for rib fracture after SBRT while
age, maximum diameter of the tumor and,radiothera-
peutic method were not statistically significant risk fac-
tors. When tumor-chest wall distance decreased by
1 mm, risk of rib fracture increased by a factor of 1.153.
This result is unsurprising, given that as the distance
decreases, the chest wall becomes more likely to receive
a high dose of radiation. In terms of sex differences, post-
menopausal women are well-known to have a higher risk
of osteoporosis due to decreased bone mineralization
compared with men. As women in our study population
were ≥55 years old, this effect most likely explains the
higher likelihood of fracture in women.
ROC analysis suggested that when using BED analysis,
an α/β ratio of 8 Gy was most effective for discriminat-
ing between fracture and non-fracture patients. The α/β
ratios for late bone damage were estimated to be within
the range of 1.8–2.8 Gy, similar to those reported for
other late-responding normal tissues [12]. Our results
appear to contradict those of previous reports. However,
it remains unclear whether the linear-quadratic model is
adaptable to hypofractionated high-dose radiotherapy,
such as SBRT to the lung. In addition, we used thin-
section CT, which is deemed as the most sensitive and
specific examination for evaluating rib fracture. This may
also partly account for the discrepancy. Our results might
suggest that another model is required to estimate risks of
rib fracture in SBRT.
No patients with BED8 <91.1 Gy developed rib fracture.
Although 91.1 Gy as a maximum BED8 for the chest wall
might suggest threshold values for rib fracture, validation
studies with a larger number of patients are required.
BED8 did not correlate significantly with the timing of
rib fracture appearance. However, we still cannot conclude
that radiation dose is unrelated to the timing of rib frac-
ture appearance, as the number of patients evaluated was
too small to reach a definitive conclusion.
Several limitations to the present study must be consi-
dered. First, for BED3 of the chest wall, not all cases from
the study population were sampled. However, we believethat our random sampling method provided a clear and
concise reference value, which would offer a benchmark
when considering risk of rib fracture in clinical practice.
Second, although we defined the non-fracture group as
cases free from rib fracture for >30 months after SBRT, a
few cases developed rib fractures after 30 months. In
addition, there is still a possibility of second peak in the
timing of rib fracture occurrence beyond our follow-up
periods. Additional cases in the non-fracture group might
develop rib fractures in the future and thus should be
included in the fracture group. This issue may have
affected our results. Third, we estimated the time at which
rib fractures and other related findings appeared as that
time at which these findings were first seen on follow-up
CT. However, these events would actually have occurred
within the intervals from the previous follow-up CT. The
present study should thus be considered to have overesti-
mated the durations to such events. Fourth, exclusion of
the 33 patients who did not participate in this study may
have affected our results. However, we think that this is
relatively unlikely, given that the reason for nonparticipa-
tion was that these patients were unable to visit our hos-
pital periodically, which was considered unrelated to the
frequency of adverse events.
Finally, methods of SBRT for lung cancer have yet to be
standardized. In fact, our radiotherapy methods varied
considerably during the period of this study. Our results
therefore cannot simply be applied to patients in other
institutions.
Conclusions
Rib fracture is seen with high frequency on follow-up CT
after SBRT to lung cancer. Risk factors for rib fracture after
SBRT include short tumor-chest wall distance, female sex
and presence of pulmonary emphysema. Clinical symptoms
are infrequent and mild. When using BED analysis, an α/β
ratio of 8 Gy was most effective for discriminating between
fracture and non-fracture patients. However, our study was
a pilot study, and thus a larger study will be required to
make definitive conclusions.
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